Biomea Fusion, Inc. (BMEA)
2.03
+0.12
(+6.28%)
USD |
NASDAQ |
Sep 04, 16:00
2.03
0.00 (0.00%)
Pre-Market: 20:00
Biomea Fusion Research and Development Expense (Quarterly) : 9.142M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.142M |
| March 31, 2026 | 9.12M |
| December 31, 2025 | 8.115M |
| September 30, 2025 | 14.40M |
| June 30, 2025 | 16.57M |
| March 31, 2025 | 22.90M |
| December 31, 2024 | 25.24M |
| September 30, 2024 | 27.24M |
| June 30, 2024 | 31.82M |
| March 31, 2024 | 33.78M |
| December 31, 2023 | 30.87M |
| September 30, 2023 | 25.35M |
| June 30, 2023 | 21.94M |
| Date | Value |
|---|---|
| March 31, 2023 | 24.40M |
| December 31, 2022 | 20.54M |
| September 30, 2022 | 18.24M |
| June 30, 2022 | 12.58M |
| March 31, 2022 | 11.35M |
| December 31, 2021 | 11.09M |
| September 30, 2021 | 7.886M |
| June 30, 2021 | 5.224M |
| March 31, 2021 | 3.798M |
| December 31, 2020 | 2.332M |
| September 30, 2020 | 0.789M |
| June 30, 2020 | 0.216M |
| March 31, 2020 | 0.334M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 52.33M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |